跳至主要内容
临床试验/NCT01713127
NCT01713127终止1 期

Efficacy and Safety of Remifentanil in Preterm Infants Who Require Ventilator Support

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2012年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
12
试验地点
1
主要终点
premature infant pain profile (PIPP)

研究概览

简要总结

The purpose of this study is to evaluate efficacy of remifentanil in preterm infants during ventilator care with remifentanil and to analyze pharmacokinetics in preterm infants

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Participant)

入排标准

年龄范围
— 至 48 Hours(Child)
性别
All
接受健康志愿者

入选标准

  • preterm infants (<37weeks of gestational age)
  • requiring ventilator care
  • informed consent

排除标准

  • major anomaly
  • 48hrs after birth
  • requiring operation during drug infusion
  • cord blood pH < 7.0
  • intraventricular hemorrhage grade III or more
  • investigators decision

研究组 & 干预措施

Placebo

Placebo Comparator

5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth

干预措施: Placebo (Drug)

remifentanil

Active Comparator

0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth

干预措施: remifentanil infusion (Drug)

结局指标

主要结局

premature infant pain profile (PIPP)

时间窗: 24hours after remifentanil/placebo infusion

PIPP measure during tracheal suction window period ; +/- 1hr

次要结局

  • pneumothorax(up to 1 week of age)
  • bronchopulmonary dysplasia(28 days of age)
  • duration of ventilator care(up to 4 months of age)
  • hospital day(upto 4 months of age)
  • development of adverse effects(from the start of remifentanil infusion to 1 hour after end of infusion)
  • intraventricular hemorrhage(up to 1 week of age)
  • time to full feeding(up to 2 months of age)
  • mortality(up to 4 months of age)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Remifentanil in Ventilated Preterm Infants | 临床试验